JP2025011315A5 - - Google Patents

Info

Publication number
JP2025011315A5
JP2025011315A5 JP2024185935A JP2024185935A JP2025011315A5 JP 2025011315 A5 JP2025011315 A5 JP 2025011315A5 JP 2024185935 A JP2024185935 A JP 2024185935A JP 2024185935 A JP2024185935 A JP 2024185935A JP 2025011315 A5 JP2025011315 A5 JP 2025011315A5
Authority
JP
Japan
Prior art keywords
cancer
composition
seq
therapeutic agents
additional therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024185935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025011315A (ja
JP7766162B2 (ja
Filing date
Publication date
Priority claimed from JP2020550713A external-priority patent/JP7328983B2/ja
Application filed filed Critical
Publication of JP2025011315A publication Critical patent/JP2025011315A/ja
Publication of JP2025011315A5 publication Critical patent/JP2025011315A5/ja
Priority to JP2025181096A priority Critical patent/JP2026016604A/ja
Application granted granted Critical
Publication of JP7766162B2 publication Critical patent/JP7766162B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024185935A 2018-03-22 2024-10-22 抗il-27抗体及びその使用 Active JP7766162B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025181096A JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862646496P 2018-03-22 2018-03-22
US62/646,496 2018-03-22
JP2020550713A JP7328983B2 (ja) 2018-03-22 2019-03-22 抗il-27抗体及びその使用
JP2023078028A JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023078028A Division JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025181096A Division JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2025011315A JP2025011315A (ja) 2025-01-23
JP2025011315A5 true JP2025011315A5 (cg-RX-API-DMAC7.html) 2025-09-03
JP7766162B2 JP7766162B2 (ja) 2025-11-07

Family

ID=67987990

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020550713A Active JP7328983B2 (ja) 2018-03-22 2019-03-22 抗il-27抗体及びその使用
JP2023078028A Active JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用
JP2024185935A Active JP7766162B2 (ja) 2018-03-22 2024-10-22 抗il-27抗体及びその使用
JP2025181096A Pending JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020550713A Active JP7328983B2 (ja) 2018-03-22 2019-03-22 抗il-27抗体及びその使用
JP2023078028A Active JP7742377B2 (ja) 2018-03-22 2023-05-10 抗il-27抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025181096A Pending JP2026016604A (ja) 2018-03-22 2025-10-27 抗il-27抗体及びその使用

Country Status (13)

Country Link
US (3) US11332524B2 (cg-RX-API-DMAC7.html)
EP (1) EP3768317A4 (cg-RX-API-DMAC7.html)
JP (4) JP7328983B2 (cg-RX-API-DMAC7.html)
KR (2) KR102879521B1 (cg-RX-API-DMAC7.html)
CN (3) CN120463807A (cg-RX-API-DMAC7.html)
AU (1) AU2019239324B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018918A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093740A1 (cg-RX-API-DMAC7.html)
IL (2) IL326896A (cg-RX-API-DMAC7.html)
MA (1) MA52094A (cg-RX-API-DMAC7.html)
MX (2) MX2020009879A (cg-RX-API-DMAC7.html)
SG (1) SG11202008707YA (cg-RX-API-DMAC7.html)
WO (1) WO2019183499A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120463807A (zh) 2018-03-22 2025-08-12 表面肿瘤学有限责任公司 抗il-27抗体及其用途
AU2019399474B2 (en) * 2018-12-13 2026-07-30 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
CA3151078A1 (en) * 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
US12240897B2 (en) * 2020-09-22 2025-03-04 Institute For Cancer Research Treatment of non-alcoholic steatohepatitis (NASH) with IL-27 antibody
AU2022270170A1 (en) * 2021-05-07 2023-09-21 Surface Oncology, LLC Anti-il-27 antibodies and uses thereof
WO2023230116A1 (en) * 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) * 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US7148330B2 (en) 1999-07-30 2006-12-12 Schering Corporation Binding compounds for IL-27
US20030008343A1 (en) 1999-07-30 2003-01-09 Timans Jacqueline C Mammalian cytokines; related reagents
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
WO2002084277A1 (en) * 2001-04-17 2002-10-24 Abmaxis, Inc. Structure-based construction of human antibody library
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
CA2511838C (en) 2002-12-31 2014-05-06 Schering Corporation Uses of mammalian cytokine; related reagents
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US20050214296A1 (en) 2004-02-17 2005-09-29 Schering Corporation Methods of modulating cytokine activity; related reagents
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB-特异性抗体及其使用方法
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20060019303A1 (en) 2004-07-23 2006-01-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in stimulated T cells
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
DE102005049800B4 (de) 2005-10-18 2009-09-17 Johannes-Gutenberg-Universität Mainz Verfahren zur Auffindung von Inhibitoren des Epstein-Barr-Virus-induzierten Gens 3 (EBI 3) und deren Verwendungen bei der Behandlung von metastasierenden Tumoren und allergischem Asthma
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2662862A1 (en) 2006-08-25 2008-02-28 Zymogenetics, Inc. Treatment of aplastic anemia
WO2008025031A1 (en) 2006-08-25 2008-02-28 Zymogenetics, Inc. Treatment of graft-versus-host disease
EP2066693A2 (en) 2006-09-22 2009-06-10 St. Jude Children's Research Hospital Modulating regulatory t cell activity via interleukin 35
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2672229A1 (en) 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
EP1987837A1 (en) * 2007-05-02 2008-11-05 Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus Pharmaceutical composition for increasing insulin secretion from pancreatic ß-cells
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010065116A2 (en) 2008-12-02 2010-06-10 The Trustees Of The University Of Pennsylvania The use of il-27-p28 to antagonize il-6 mediated signaling
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
US20120189578A1 (en) 2009-08-24 2012-07-26 St. Jude Children's Research Hospital Compositions and methods for potentiating interleukin-35
AU2010306563B2 (en) 2009-10-15 2013-11-28 Circle 33, Llc Antibody therapeutics with local activity in the digestive tract
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011133931A1 (en) * 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011140151A1 (en) * 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
WO2012097238A2 (en) * 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP2700409A1 (en) 2012-08-23 2014-02-26 Deutsches Rheuma-Forschungszentrum Berlin IL-27 for modulation of immune response in acute lung disease
WO2014070874A1 (en) 2012-10-31 2014-05-08 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
JP6605957B2 (ja) 2013-01-04 2019-11-13 シトムクス セラピューティクス,インコーポレイティド 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
CA2903359A1 (en) 2013-05-27 2014-12-04 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Targeted modulation of macrophages
EP3041501B1 (en) 2013-09-05 2019-03-27 Dendreon Pharmaceuticals, Inc. Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2015168503A1 (en) 2014-05-02 2015-11-05 Batu Biologics Compositions and means for induction of tumor immunity
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI695011B (zh) * 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
WO2016004389A2 (en) 2014-07-03 2016-01-07 Abbvie Inc. Monovalent binding proteins
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
WO2017025698A1 (en) 2015-08-11 2017-02-16 Queen Mary University Of London Bispecific, cleavable antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
WO2017196432A1 (en) 2016-05-12 2017-11-16 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating neurodegenerative disease
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
EP3522925A4 (en) 2017-01-10 2020-06-10 National Yang-Ming University METHOD FOR TREATING CANCER METASAS AND COMPOSITION THEREOF
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
CN120463807A (zh) 2018-03-22 2025-08-12 表面肿瘤学有限责任公司 抗il-27抗体及其用途
AU2019399474B2 (en) 2018-12-13 2026-07-30 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
Koganemaru et al. U3-1402, a novel HER3-targeting antibody–drug conjugate, for the treatment of colorectal cancer
Yang et al. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
Li et al. IDO1: an important immunotherapy target in cancer treatment
Xie et al. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
Massari et al. Immune checkpoint inhibitors for metastatic bladder cancer
Antonia et al. Immuno-oncology combinations: a review of clinical experience and future prospects
RU2723021C2 (ru) Применение плинабулина в комбинации с ингибиторами контрольной точки иммунного ответа
JP2024178243A (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
KR20220044481A (ko) 암 면역요법을 위한 조성물 및 방법
Reguera-Nuñez et al. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
EP3641770A1 (en) Methods for treating cancer
CA3101340A1 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
JP2020514289A5 (cg-RX-API-DMAC7.html)
CN107801379A (zh) 抗癌剂
JP2021518138A5 (cg-RX-API-DMAC7.html)
Morganti et al. Combinations using checkpoint blockade to overcome resistance
JP2023548051A (ja) 肺がんのためのlag-3アンタゴニスト療法
Sorrentino et al. Uveal melanoma: Recent advances in immunotherapy
JP2022549854A5 (cg-RX-API-DMAC7.html)
Valdivia et al. Treatment strategies in cervical cancer: treatment of advanced disease
Zheng et al. Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC
Gonsalves et al. Targeted anti-cancer therapy in the elderly
Francis et al. The current status of targeted therapy for non‐small cell lung cancer
Schwartz et al. 4-1BB antibodies in oncology clinical trials: a review
WO2025186213A1 (en) Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor